仁和药业：公司2021年获得恩替卡韦片药品注册证书，该药物用于治疗乙肝感染

Core Viewpoint - The company has received a drug registration certificate for Entecavir tablets in 2021, which is used for the treatment of hepatitis B infection [2]. Company Products - Entecavir is an oral antiviral medication that selectively inhibits the hepatitis B virus, primarily used for treating adults with active viral replication and elevated serum transaminases, or active disease in liver histology [2].